Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure? – Yahoo Finance

Biotech bigwig Bristol Myers BMY has had a decent run this year despite one of its top drugs Revlimid facing generic competition, which has adversely impacted the top line.
Revlimid was the largest contributor to the company’s revenues, and the entry of generics for the company had clouded the growth trajectory somewhat.
Bristol Myers seems to have more arrows in its quiver. As expected, the performance of blood thinner drug Eliquis and immuno-oncology drug Opdivo, along with encouraging pipeline progress, has maintained momentum.
But what has impressed the investors most is the recent string of new drug approvals, which paved the way for an incremental stream of revenues.  The FDA recently approved its experimental candidate deucravacitinib to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, under the brand name Sotyktu. Sotyktu is also under regulatory review by the European Medical Association and other health authorities worldwide.
The approval is based on results from the phase III POETYK PSO-1 and POETYK PSO-2 studies, demonstrating superior efficacy of once-daily Sotyktu over placebo and twice-daily Amgen’s AMGN Otezla (apremilast) in 1,684 patients, aged 18 years and above, with moderate-to-severe plaque psoriasis. Bristol Myers added deucravacitinib to its pipeline when it acquired Celgene in 2019 and had to let go of Otezla.  In connection with the regulatory approval process for the transaction, Celgene sold the global rights to Otezla to Amgen. The risk should reap rewards with this new drug approval.
The FDA had earlier approved a new, first-in-class, fixed-dose combination of PD-1 inhibitor Opdivo (nivolumab) and relatlimab (novel LAG-3-blocking antibody). It is administered as a single intravenous infusion to treat adult and pediatric patients aged 12 years or older with unresectable or metastatic melanoma (a kind of skin cancer) under the brand name Opdualag.  The initial uptake f the drug has been encouraging so far. The drug was also approved in Europe.
Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) was also approved in the United States for treating adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.
The uptake of the new product portfolio (primarily cell therapy products and Reblozyl) has also boosted sales.
Bristol Myers had earlier acquired Turning Point Therapeutics for $4.1 billion. The acquisition added Turning Point’s lead asset, repotrectinib, a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 and NTRK oncogenic drivers of NSCLC and other advanced solid tumors. The deal should strengthen Bristol Myers’ position in the oncology space, particularly in the lucrative lung cancer arena.
Meanwhile, Eliquis has delivered a stellar performance so far in 2022, propelled by increases in share in the novel oral anticoagulant market.  Label expansion of Opdivo boosted sales driven by higher demand across multiple indications, including the Opdivo+Yervoy-based combinations for non-small cell lung cancer (NSCLC), Opdivo+Cabometyx combination for kidney cancer and Opdivo-based therapies for various gastric and esophageal cancers.
However, competition is stiff for Opdivo from the likes of Merck’s MRK Keytruda. The drug, approved for various oncology indications, is the key driver for Merck.
The diversification of the portfolio should enable the company to combat these challenges.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Related Quotes
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
If you want to know who really controls Bristol-Myers Squibb Company ( NYSE:BMY ), then you'll have to look at the…
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
The entertainment company’s $55 million deal follows a wave of consolidation in the publishing world.
Polen Capital, an investment management company, released its “Polen Focus Growth Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund returned -23.94% net of fees compared to a -16.10% return for the S&P 500 and -20.92% return for the Russell 1000 Growth Index. […]
The Government of Canada is committed to engaging Canadians in the pursuit of an improved regulatory system that is transparent, efficient, consistent and competitive.
There wouldn't be many who think Merck & Co., Inc.'s ( NYSE:MRK ) price-to-earnings (or "P/E") ratio of 13.1x is worth…
Beaten-down valuations are likely to be temporary given that supply-demand dynamics in the semiconductor industry are improving.
AstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium. AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million. Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats.
Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.
The stock market is often a game in reverse psychology. That is, when the mood gets too euphoric, it’s often a sign it is time to sell. Likewise, when sentiment hits the skids, that could be the ultimate signal the time is right to load up the truck. And on that subject, J.P. Morgan’s Marko Kolanovic thinks we are at – or at least near – the bottom. The firm’s global market strategist believes the Fed’s hawkish stance has left stocks “very oversold,” and while inflation remains persistently high
Aura Biosciences Inc (NASDAQ: AURA) detailed interim data from its ongoing Phase 2 trial of an eye cancer drug, elzupacap sarotalocan (AU‑011). Belzupacap sarotalocan controlled tumors in most patients on longer treatment cycles. Nearly all patients retained their vision in an interim look at the Phase 2 trial, with a data cutoff of Aug. 19, at the American Academy of Ophthalmology conference in the Second City. Two of the nine patients received 40 μg, and the other seven were given 80 μg. Accor
The cruise line cites 'significant, positive progress in the public-health environment' as part of its decision to loosen its public-health policy.
On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.
Wilmington biotech company Incyte has agreed to acquire Villaris Therapeutics in a deal valued at up to $1.36 billion. The centerpiece of the deal is auremolimab, a monoclonal antibody that is under development to treat the skin disorder vitiligo — but has potential applications beyond dermatology. Villaris, based in Cary, North Carolina, was founded in 2019 and is backed by Medicxi, a health care-focused investment firm based in London.
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
The condition is as common as it is embarrassing—but it’s not something you have to live with indefinitely.
While largely a bill intended to combat climate change, the Inflation Reduction Act instituted several big changes for Medicare.
The vegetable was shown to lower blood sugar levels and cholesterol levels


Add a Comment

Your email address will not be published. Required fields are marked *